Sequrna

Executive Summary

Sequrna, a Stockholm-based private biotech founded in 2018, specializes in high-performance thermostable RNase inhibitors designed for reliable RNA protection in demanding molecular biology applications. The company's proprietary inhibitors are ideal for single-cell RNA-seq and in situ sequencing, addressing critical needs in genomics and diagnostics where RNA integrity is paramount. By offering a solution that maintains RNA stability under harsh conditions, Sequrna enables more accurate and reproducible results in research and clinical workflows. As the demand for single-cell analysis and spatial transcriptomics grows, Sequrna's technology positions it as an enabler for cutting-edge biological discovery. The company's focus on thermostability differentiates its products from conventional RNase inhibitors, which often require cold chain logistics and have limited efficacy in high-temperature protocols. This niche application area, combined with the expansion of RNA-based diagnostics and therapeutics, provides a strong market opportunity. While Sequrna is still early-stage with no disclosed funding or pipeline details, its technology addresses a clear unmet need in the rapidly evolving genomics toolkit.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of next-generation RNase inhibitor optimized for single-cell RNA-seq70% success
• Q2 2027Strategic partnership with a major sequencing platform provider for co-marketing or integration50% success
• Q3 2026Closing of Series A funding round to scale production and sales80% success